A years-long collaboration between some of Australia’s leading experts in stem cell biology, ophthalmology, and computational biology has produced a genetic roadmap for age-related macular degeneration (AMD) that could be a gamechanger for the discovery of novel treatments.
Vabysmo is a new treatment for age-related macular degeneration and diabetic macular oedema and is now available on the Pharmaceutical Benefits Scheme (PBS) in Australia
MDFA 2022 research update
MDFA welcomed Dr Kathy Chapman as CEO in July
Attend any medical congress and you’ll increasingly hear the terms “artificial intelligence” and “digital diagnosis”
Ophthalmologists needed for IVI digital support program
MDFA is partnering with MyInteract to provide targeted digital information and resources directly to people receiving intravitreal injections (IVI).
Free vision screenings at NSW Parliament House on World Sight Day.
MDFA’s successful advocacy leading to the new Government’s rejection of the proposal to cut the MBS rebate for intravitreal injections leaves us with the question: what next?